Multiple Myeloma Research Consortium to Present Data Eight Oral or Poster bi13752243 NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced that eight abstracts from clinical collaborations academia and industry have been accepted for oral and poster presentations at year's American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2011 San Diego, California. In an oral presentation, the MMRC ..

Scientists defeat hurdle to eradicating inactive multiple myeloma cells bi13752243 Researchers at Virginia Commonwealth University Massey Cancer Center have developed a novel strategy for multiple myeloma that delivers a deadly one-two blow to kill even the most inactive, or cytokinetically quiescent, cells. Because multiple myeloma can rest a non-proliferative state for extended periods of time, discovery may help to overcome a major hurdle to treating ..

Multiple Myeloma Research Consortium Welcomes Karmanos Cancer Institute as Me bi13752243 The Multiple Myeloma Research Consortium today announced that has expanded clinical research network to include the Barbara Ann Karmanos Cancer Institute Detroit

Onyx Pharma Says FDA Accepts NDA For Carfilzomib To Treat Multiple Myeloma bi13752243 Onyx Pharma Says FDA Accepts NDA For Carfilzomib To Treat Multiple Myeloma..

Multiple Myeloma - First Risk Genes Discovered bi13752243 According to a paper published online Nature Genetics, a team of scientists led by The Institute of Cancer Research (ICR) has demonstrated for the first time that a person's genes influence risk of developing multiple myeloma, a cancer of plasma cells, a type of white blood cell responsible for the production of antibodies. Each year, approximately 4,000 people the UK are ..

Senesco to Present at the 53rd Annual Meeting of the American Society of Hema bi13752243 Senesco Technologies, Inc. ("Senesco or the "Company) (NYSE AMEX: SNT) announced today that deliver a poster presentation at the 53rd Annual ..

Multiple Myeloma treatment gets a much needed boost bi13752243 More often than not, the general public forgets takes more to fix an illness than just medication. That medication or must be clinically approved and tested, a process could take several years

Multiple Myeloma Research Consortium (MMRC) Opens Record-Breaking Number of T bi13752243 The Multiple Myeloma Research Consortium today announced that opened more multiple myeloma clinical trials at member institutions during 2011 than any other year the Consortium was founded 2004

The Multiple Myeloma Research Foundation (MMRF) Announces Four Leading Academ bi13752243 The Multiple Myeloma Research Foundation today announced that four leading cancer centers are enrolling patients as part of the landmark 1,000-patient study designed to characterize the genetic variation multiple myeloma

Multiple Myeloma Research Consortium (MMRC) Honors Dr. Ravi Vij, Washington U bi13752243 The Multiple Myeloma Research Consortium today announced that has awarded Washington University School of Medicine St. Louis and Ravi Vij, MD, the 2011 MMRC Center of the Year Award

Emerging lymphoma and myeloma treatments focus on improving individual patien bi13752243 ( American Society of Hematology ) Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made the of these diseases, they remain a significant challenge for patients and hematologists. New research introducing unique ..

Myeloma Foundation Adds Genomics Study Cancer Centers bi13752243 NEW YORK (GenomeWeb News) ? The Multiple Myeloma Research Foundation (MMRF) has added four new cancer centers to a study leading to seek out genetic variants involved multiple myeloma, be responsible for the deaths of an estimated 11,000 people year

Takeda drug cuts myeloma death risk 5-year study bi13752243 (Reuters) - Takeda Pharmaceutical Co's Velcade reduced the risk of death by 31 percent when used combination standard medicines previously untreated multiple myeloma patients, according to five-year follow-up data from a late stage clinical trial. The survival benefit patients who received Velcade, known chemically as bortezomib, was observed all analyzed subgroups, including ..

Brake Pad Change - Home